Navigation Links
Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
Date:11/2/2008

Novartis notified of data set closing, Top-line results expected in

November

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has closed the data set for preliminary analysis of the primary endpoint in the phase III EXTEND (PIX301) trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL) and it has provided Novartis notice that the data set has been closed. The primary endpoint for the study is the complete remission (CR) and unconfirmed complete remission (uCR) rate in patients receiving either pixantrone or another single agent chemotherapeutic drug. CTI plans to report top-line results in November.

"We are excited to have reached the end of the treatment phase and follow-up period for the pixantrone pivotal study and look forward to reporting top-line results in November," said James A. Bianco, M.D., CEO of Cell Therapeutics. "Complete remissions in this patient population with end stage advanced disease are seldom accomplished with the current standard of care. Pixantrone, if successful in achieving the study objectives, could offer these patients a significant benefit, and we would work with the FDA to submit an NDA in 2009."

CTI has an existing license and co-development agreement with Novartis for OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. Patients were randomized to receive either pixantr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
5. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
6. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
7. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
8. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
9. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
10. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
11. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)...  Elekta has CE marked the latest version (v5.10) ... enabling European clinics to deliver a sophisticated radiation therapy ... 3D planning, IMRT, VMAT and stereotactic planning – all ... Monaco ® v5.10 provides significant planning ... in 3D planning as well as the addition of ...
(Date:4/23/2015)... April 23, 2015  ResMed Inc. (NYSE: RMD ... 31, 2015.  Revenue for the quarter was $422.5 million, ... March 31, 2014 (a 13 percent increase on a ... increase of 1 percent compared to the quarter ended ... quarter were $0.64, an increase of 2 percent compared ...
(Date:4/23/2015)... April 23, 2015 Nektar Therapeutics (Nasdaq: NKTR ... ended March 31, 2015 on Thursday, April 30, 2015, after ... president and chief executive officer, will host a conference call ... (ET)/2:00 p.m. Pacific Time (PT). The press ... can be accessed through a link that is posted on ...
Breaking Medicine Technology:Elekta CE marks for Monaco v5.10 treatment planning system 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... 5, 2011 Express Scripts contributed more than $226 ... economic analysis of the company,s data by a university ... The economic impact study, presented today to state economic ... support 2,665 direct and indirect jobs in the state. ...
... NeuroVasx announced today that the FDA ... Humanitarian Use Device (HDE) for the treatment of large, ... most difficult to treat.  The HDE allows for the ... the U.S. (Logo: http://photos.prnewswire.com/prnh/20110405/CG77724LOGO ) ...
Cached Medicine Technology:Express Scripts Injects $226 Million Into Arizona Economy, Study Finds 2NeuroVasx Receives FDA Approval for cPAX Aneurysm Treatment System 2
(Date:4/26/2015)... Indiana (PRWEB) April 26, 2015 Indiana ... service provider announces that Brotherhood Mutual Insurance Company has ... Armstrong, Manager of Network Infrastructure at Brotherhood Mutual Insurance ... and the service reliability Brotherhood Mutual needed. ... diversity, and IFN worked with us to ensure we ...
(Date:4/26/2015)... FL (PRWEB) April 26, 2015 A ... pieces of medical equipment from hospitals, surgery centers and ... of equipment will be sold including radiology, surgery, endoscopy, ... live auction will take place Tuesday, April 28th starting ... Lauderdale warehouse located at 5025 North Hiatus Rd., Sunrise, ...
(Date:4/26/2015)... In an article published last month ... head-neck biomechanics occurring during the use of handheld electronic devices ... determine that use of a tablet increases mechanical demand on ... - more than when the neck is in a neutral ... but pointing out the potential hazards of overuse of mobile ...
(Date:4/26/2015)... MidSouth Pain Treatment Center has announced ... Treatment Center is a comprehensive pain management center including ... two ambulatory surgery centers in Germantown and Southaven, and ... , Dr. Michael Steuer , founder of MidSouth ... people, and when I discovered that I could make ...
(Date:4/25/2015)... California (PRWEB) April 26, 2015 Avid ... search for original 1965 Rolling Stones Greensboro Coliseum concert posters. ... was part of the Stone's Second American Tour. ... Globe Poster Company out of Baltimore, Maryland. This poster ... the northeast and southern cites. Globe uses garish lettering ...
Breaking Medicine News(10 mins):Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Growing Pains for MidSouth Pain Treatment Center 2
... Enjoying the eating process without focus on dietary restrictions ... according to researchers who have unveiled a new and ... Competence Model, also known as ecSatter, was created by ... of Secrets of Feeding a Healthy Family, Kelcy ...
... Significant Data Detailed at a Late-Breaking Presentation at ... ... 18 Iomai,Corporation (Nasdaq: IOMI ) today announced that travelers ... be sickened as compared with travelers who receive a placebo,according to ...
... (NYSE: AGP ) today announced that it ... and Medicare Services (CMS) to offer both,Medicare Advantage ... plans to address the specialized needs of seniors ... currently coordinates care for approximately 5,000,individuals through Medicare ...
... N.C., Sept. 18 Contact centers have been,transformed ... movement,that has reps selling while conducting ongoing customer ... skills are critical for,converting service reps to sales ... Practices, LLC. Ninety-eight percent of the 57 ...
... Researchers at the University of Pennsylvania School of ... Quality (AHRQ) have developed a framework to help ... challenges of implementing health information technology (HIT) by ... and quality. , As documented in a ...
... WASHINGTON, Sept. 18, 2007 -- A long-term study found ... patients with life-threatening diseases, such as leukemia and lymphoma, ... Further, males are likely to recover from these changes ... compromised. In addition, neither male nor female long-term cancer ...
Cached Medicine News:Health News:Nutrition model stresses positive experience of eating 2Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 2Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 3Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 4Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 5Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 2Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 3Health News:Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills 2Health News:Unanticipated consequences of health-care information technology 2Health News:Sexual function affected by stem cell transplant according to long-term study 2Health News:Sexual function affected by stem cell transplant according to long-term study 3Health News:Sexual function affected by stem cell transplant according to long-term study 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: